Authors state that with equivalent efficacy, shorter courses could be an option for more patients. However, the risk-benefit balance is close and needs to be considered on an individual basis. Longer treatment might still be preferable for some people with prior heart attack who are at higher risk of future cardiovascular events and low risk of bleeding.